The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I think this explains in better detail.
Synairgen considers developing its inhaled interferon beta for COPD
Synairgen has announced that it is considering development of its SNG001 inhaled interferon beta for the treatment of COPD. SNG001 was previously in development for the prevention of exacerbations caused by viral lung infections in asthma patients.
In 2012, the company announced positive results from a Phase 2 study demonstrating that SNG001 produced statistically significant improvement in symptom reduction, the use of reliever inhalers, and lung function compared to placebo in asthma patients suffering from a cold.
In 2014, AstraZeneca licensed SNG001 for the treatment of viral respiratory tract infections in severe asthma patients; however, AstraZeneca halted the Phase 2a INEXAS trial after an unexpectedly low rate of severe exacerbations brought the trial design into question.
Synairgen now says that “the unexpectedly low exacerbation rate (<10%) in the INEXAS trial population suggests that the economic viability of the drug in an asthma indication would be limited.”
According to the company, recent data and diagnostic improvements now make COPD “a very attractive market” that could be targeted more accurately than in the past, and it plans to initiate a short trial of SNG001 later this year or in early 2018.
Synairgen CEO Richard Marsden commented, “We have long been conscious that COPD is the key target market for a broad spectrum antiviral such as SNG001. Until recently, the difficulties of patient selection and the associated cost of the required trials made it prohibitively expensive to pursue. The fact that high viral exacerbation rates are now evident, combined with the launch of an effective diagnostic for viral infections, means that a COPD program is now both highly attractive and economically viable.”
Read the Synairgen press release.
Well I've been invested in this share since 2016, but I don't think there's anything "high level" in it - it's all in the RNSs, interviews, etc.
SDG27. Blimey, how do you know such detail about all this as it’s pretty high level stuff! :). Thanks
yes agree i've seen the results stop the trials early, Sng are now in a good position dyor
It's a long story but to summarise, it was basically a problem with the trial rather than the drug. Not enough of the asthma sufferers in the trial got the right sort of virus-based exacerbations to give a conclusive result.
By the time of the COPD trial there was a test for virus vs other. So they have a pool of COPD sufferers on standby. When one of them suffers an exacerbation they can be tested, and if it's a virus then they enter the trial. So far they have 109 out of a 120 target, but it's paused to make way for the COVID19 trial.
It's possible they'll return to asthma again, if they think there's a big enough market for asthma plus virus-based exacerbations.
(Not an expert, so happy to be corrected if any of this is wrong. DYOR)
PS I see John117 has posted similarly while I was putting this together.
It’s you dude. Basically it worked but they were struggling to find unwell people to test it on. COPD and COVID will not face that problem. Also that deal was with AZN and was worth some 230mil before AZN pulled out due to worries about market size. DYOR.
Great to see, but this doesnt read so well or is it just me?
Asthma phase II trial:
Djukanovic et al. Am J Respir
Crit Care Med. 2014.190(2)
:145-54 ;
NCT01126177
Asthma: Phase II trials
(SG005 and INEXAS) in
asthma, conducted by
Synairgen (NCT01126177)
and AstraZeneca
respectively, suggest that
SNG001 boosts antiviral
responses in the lungs, has a
beneficial effect on lung
function and, in more
difficult to treat patients,
improves asthma control
during cold infections.
However, the unexpectedly
low exacerbation rate (<10%)
in the INEXAS trial population
suggests that the economic
viability of the drug in an
asthma indication would be
limited.
(https://www.synairgen.com
/programmes/ifn-%CE%B2-
in-copd/)
RNS Number : 5374G
Synairgen plc
18 March 2020
SNG001 was identified in the WHO's Landscape analysis of therapeutics as at 17 February 2020 as the only Phase 2/Phase 3/Observational therapy delivered by the inhaled route
https://www.who.int/blueprint/priority-diseases/key-action/Table_of_therapeutics_Appendix_17022020.pdf?ua=1